INDIVIDUALIZED GENETIC MAKEUP THAT CONTROLS NATURAL KILLER CELL FUNCTION INFLUENCES THE EFFICACY OF ISATUXIMAB IMMUNOTHERAPY IN PATIENTS WITH MULTIPLE MYELOMA

被引：0

作者：

Rajalingam, R. ^{[1
]}

Sun, H. ^{[1
]}

Kong, D. ^{[1
]}

Mace, S. ^{[2
]}

Chiron, M. ^{[2
]}

机构：

[1] Univ Calif San Francisco, Immunogenet & Transplantat Lab, San Francisco, CA 94143 USA

[2] Sanofi Res & Dev, Translat & Expt Med, Cambridge, MA USA

来源：

HUMAN IMMUNOLOGY | 2021年 / 82卷

关键词：

D O I：

暂无

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

P49

引用

页码：103 / 104

页数：2

共 50 条

[41] CONTINUOUS MAINTENANCE THERAPY WITH ALTERNATE-DAY LOW DOSE LENALIDOMIDE IN MULTIPLE MYELOMA PATIENTS AFTER AUTOLOGOUS STEM CELL TRANSPLANTATION INCREASES THE NUMBER OF CIRCULATING NATURAL KILLER CELLS [J].

Pezzullo, L. ;

Fontana, R. ;

Serio, B. ;

Annunziata, S. ;

Sessa, M. ;

Ferrara, I. ;

Giudice, V. ;

Esposito, B. ;

Villani, G. ;

Rocco, M. ;

Selleri, C. .

BONE MARROW TRANSPLANTATION, 2014, 49 :S353-S353

[42] A Systematic Review and Meta-analysis on the Safety and Efficacy of CAR T Cell Therapy Targeting GPRC5D in Patients with Multiple Myeloma: A New Insight in Cancer Immunotherapy [J].

Robat-Jazi, Behrouz ;

Mahalleh, Mehrdad ;

Dashti, Mohsen ;

Nejati, Negar ;

Ahmadpour, Mahsa ;

Alinejad, Erfan ;

Mohammadi, Shiva ;

Lorestani, Parsa ;

Hamidieh, Amir Ali ;

Habibi, Mohammad Amin ;

Jadidi-Niaragh, Farhad .

ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY, 2025, 25 (14) :1017-1028

[43] Pre-Clinical Efficacy of AB-101, an Allogeneic Cord-Blood Derived Natural Killer (NK) Cell Therapeutic Candidate, in Combination with Anti-CD38 Antibodies in Models of Multiple Myeloma [J].

Chu, Gina ;

Teng, Kun-Yu ;

Guerrettaz, Lisa ;

Da Silva, Rodrigo Fernades ;

Rotondo, Salvatore ;

La Torre, Claudia Palomino ;

Conerty, Amanda ;

Flynn, Peter ;

Seto, Anita ;

Raymon, Heather ;

Somanchi, Srinivas .

BLOOD, 2022, 140 :7419-7420

[44] Efficacy and Safety of Isatuximab, Carfilzomib, and Dexamethasone (IsaKd) in Multiple Myeloma Patients at the First Relapse After Autologous Stem Cell Transplantation and Lenalidomide Maintenance: Results from the Multicenter, Real-Life AENEID Study (vol 18, 595, 2025) [J].

Sgherza, Nicola ;

Battisti, Olga ;

Curci, Paola ;

Conticello, Concetta ;

Palmieri, Salvatore ;

Derudas, Daniele ;

Germano, Candida ;

Martino, Enrica Antonia ;

Mele, Giuseppe ;

Della Pepa, Roberta ;

Fazio, Francesca ;

Mele, Anna ;

Rossini, Bernardo ;

Palazzo, Giulia ;

Roccotelli, Daniela ;

Rasola, Simona ;

Petrucci, Maria Teresa ;

Pastore, Domenico ;

Tarantini, Giuseppe ;

Pane, Fabrizio ;

Gentile, Massimo ;

Raimondo, Francesco Di ;

Resta, Emanuela ;

Musto, Pellegrino .

PHARMACEUTICALS, 2025, 18 (06)

[45] Final Report of Safety and Efficacy From a Novel Conditioning Regimen, Individualized Once-Daily Intravenous Busulfan with Bortezomib, in Relapsed Multiple Myeloma Patients Undergoing a Second Autologous Hematopoietic Stem Cell Transplantation. [J].

Stadtmauer, Edward A. ;

Ratanatharathorn, Voravit ;

Yeh, Rosa F. ;

Freytes, Cesar O. ;

Toro, Juan J. ;

Akpek, Gorgun ;

Sahovic, Entezam A. ;

Tricot, Guido J. ;

Shaughnessy, Paul J. ;

White, Darrell J. ;

Rodriguez, Tulio E. ;

Solomon, Scott R. ;

Yu, Louie H. ;

Patil, Shiva ;

Sun, Yiping ;

Armstrong, Elizabeth ;

Smith, Angela ;

Elekes, Agnes ;

Kato, Kazunobu ;

Reece, Donna .

BLOOD, 2012, 120 (21)

[46] Limited efficacy of APRIL CAR in patients with multiple myeloma indicate challenges in the use of natural ligands for CAR T-cell therapy (vol 11, e006699, 2023) [J].

Lee, L. ;

Lim, W. C. ;

Galas-Filipowicz, D. .

JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2023, 11 (07)

[47] Efficacy and Safety of the Natural Killer T Cell-Stimulatory Glycolipid OCH-NCNP1 for Patients With Relapsing Multiple Sclerosis: Protocol for a Randomized Placebo-Controlled Clinical Trial [J].

Okamoto, Tomoko ;

Ishizuka, Takami ;

Shimizu, Reiko ;

Asahina, Yasuko ;

Nakamura, Harumasa ;

Shimizu, Yuko ;

Nishida, Yoichiro ;

Yokota, Takanori ;

Lin, Youwei ;

Sato, Wakiro ;

Yamamura, Takashi .

JMIR RESEARCH PROTOCOLS, 2024, 13

[48] Challenges in αCD38-chimeric antigen receptor (CAR)-expressing natural killer (NK) cell-based immunotherapy in multiple myeloma: Harnessing the CD38dim phenotype of cytokine-stimulated NK cells as a strategy to prevent fratricide [J].

Karvouni, Maria ;

Vidal-Manrique, Marcos ;

Susek, Katharina H. ;

Hussain, Alamdar ;

Gilljam, Mari ;

Zhang, Yanliang ;

Gray, J. Dixon ;

Lund, Johan ;

Kaufmann, Gunnar ;

Ljunggren, Hans-Gustaf ;

Ji, Henry ;

Lundqvist, Andreas ;

Wagner, Arnika K. ;

Guo, Wenzhong ;

Alici, Evren .

CYTOTHERAPY, 2023, 25 (07) :763-772

[49] Phase 1 study to evaluate the safety and efficacy of immunotherapy with tremelimumab and durvalumab in multiple myeloma patients receiving high dose chemotherapy and autologous stem cell transplant (HDT/ASCT) plus peripheral blood lymphocyte (PBL) reinfusion. [J].

Lesokhin, Alexander M. ;

Chung, David J. ;

Cho, Hearn J. ;

Shohara, Lisa ;

Schwarzenberger, Paul .

JOURNAL OF CLINICAL ONCOLOGY, 2017, 35

[50] Phase II study of umbilical cord blood-derived natural killer (CB-NK) cells with elotuzumab, lenalidomide, and high-dose melphalan followed by autologous stem cell transplantation (ASCT) for patients with high-risk multiple myeloma (HRMM). [J].

Srour, Samer Ali ;

Mehta, Rohtesh S. ;

Shah, Nina ;

Qazilbash, Muzaffar H. ;

Im, Jin ;

Bashir, Qaiser ;

Saini, Neeraj ;

Nieto, Yago ;

Khouri, Issa F. ;

Daher, May ;

Kebriaei, Partow ;

Popat, Uday R. ;

Manasanch, Elisabet Esteve ;

Lee, Hans C. ;

Thomas, Sheeba K. ;

Orlowski, Robert Z. ;

Champlin, Richard E. ;

Shpall, Elizabeth J. ;

Rezvani, Katy .

JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)

← 1 2 3 4 5 →